

#### Synonym

KDR,CD309,FLK1,VEGFR,VEGFR2

#### Source

Human VEGF R2 Protein, Twin-Strep Tag(KDR-H5280) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823).

Predicted N-terminus: Ala 20

#### **Molecular Characterization**

VEGF R2(Ala 20 - Glu 764) AAI31823

Twin-Strep

This protein carries a twin strep tag at the C-terminus.

The protein has a calculated MW of 86.3 kDa. The protein migrates as 120-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

#### **Endotoxin**

Less than 1.0 EU per µg by the LAL method.

### **Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

#### **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

### Storage


For long term storage, the product should be stored at lyophilized state at -20 $^{\circ}$ C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


# SDS-PAGE



Human VEGF R2 Protein, Twin-Strep Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

# **Bioactivity-ELISA**

#### **SEC-MALS**




The purity of Human VEGF R2 Protein, Twin-Strep Tag (Cat. No. KDR-H5280) is more than 90% and the molecular weight of this protein is around 120-135 kDa verified by SEC-MALS.

Report

# Human VEGF R2 / KDR Protein, Twin-Strep Tag (MALS verified)







Immobilized ActiveMax® Human VEGF121, Tag Free (Cat. No. VE1-H4213) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind Human VEGF R2 Protein, Twin-Strep Tag (Cat. No. KDR-H5280) with a linear range of 0.15-2.5  $\mu$ g/mL (QC tested).

### **Background**

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGFA binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

### **Clinical and Translational Updates**

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.